These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 551917)

  • 1. Drug metabolism: an industrial research view of the future.
    Ober RE
    Drug Metab Rev; 1979; 10(2):315-9. PubMed ID: 551917
    [No Abstract]   [Full Text] [Related]  

  • 2. Towards a more rational regulation of the development of new medicines. Report of a European workshop held in Sestri Levante, Italy, September 28-30, 1976.
    Eur J Clin Pharmacol; 1977 Mar; 11(3):233-8. PubMed ID: 852499
    [No Abstract]   [Full Text] [Related]  

  • 3. [Research of for the discovery of new drugs and research for the development and production of drugs].
    Setnikar I
    Boll Chim Farm; 1971 Sep; 110(9):503-9. PubMed ID: 5137987
    [No Abstract]   [Full Text] [Related]  

  • 4. Bioavailability of drugs: principles and problems. Report of a WHO Scientific Group.
    World Health Organ Tech Rep Ser; 1973 Nov; 536():1-17. PubMed ID: 4204708
    [No Abstract]   [Full Text] [Related]  

  • 5. Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism.
    Baillie TA
    Chem Res Toxicol; 2008 Jan; 21(1):129-37. PubMed ID: 18052111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guidelines for evaluation of drugs for use in man. Report of a WHO scientific group.
    World Health Organ Tech Rep Ser; 1975; (563):1-59. PubMed ID: 803745
    [No Abstract]   [Full Text] [Related]  

  • 7. Brain to bottle time.
    Burt RA
    Proc R Soc Med; 1974 Jun; 67(7):584-6. PubMed ID: 4211842
    [No Abstract]   [Full Text] [Related]  

  • 8. [Metabolism of drugs and drug security].
    Rentsch GA
    Dtsch Med Wochenschr; 1975 Oct; 100(44):2285-92. PubMed ID: 1183328
    [No Abstract]   [Full Text] [Related]  

  • 9. [Toxicology animal studies necessary for clinical research and registration of drugs for human use: conclusions of the International Harmonization Conference (I)].
    Rubio Terrés C; Duque I; Tristán C; Galende I
    Med Clin (Barc); 1993 Nov; 101(18):705-16. PubMed ID: 8114529
    [No Abstract]   [Full Text] [Related]  

  • 10. The pharmacological and toxicological significance of the stereochemistry of drug disposition.
    Caldwell J; Winter SM; Hutt AJ
    Xenobiotica; 1988 Jan; 18 Suppl 1():59-70. PubMed ID: 3344590
    [No Abstract]   [Full Text] [Related]  

  • 11. Current and future trends in the application of HPLC-MS to metabolite-identification studies.
    Castro-Perez JM
    Drug Discov Today; 2007 Mar; 12(5-6):249-56. PubMed ID: 17331890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Studies on the biotransformation of drugs and its significance in pharmaceutical industry].
    Hansen T
    Nord Med; 1967 Nov; 78(47):1549-54. PubMed ID: 6075279
    [No Abstract]   [Full Text] [Related]  

  • 13. Animal data in perspective.
    Uehleke H
    Int J Clin Pharmacol; 1973 Nov; 8(3):239-43. PubMed ID: 4772084
    [No Abstract]   [Full Text] [Related]  

  • 14. The state of the art: a commentary on the current practice of metabolism and pharmacokinetic studies in the pharmaceutical industry.
    Case DE
    Xenobiotica; 1981 Dec; 11(12):803-14. PubMed ID: 7342486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Some fundamental concepts in pharmacokinetics].
    Hirtz J
    Nouv Presse Med; 1977 Jun; 6(26):2335-8. PubMed ID: 887419
    [No Abstract]   [Full Text] [Related]  

  • 16. In silico toxicology for the pharmaceutical sciences.
    Valerio LG
    Toxicol Appl Pharmacol; 2009 Dec; 241(3):356-70. PubMed ID: 19716836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.
    Buckley LA; Dorato MA
    Regul Toxicol Pharmacol; 2009 Aug; 54(3):301-7. PubMed ID: 19477212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimizing the potential for metabolic activation as an integral part of drug design.
    Evans DC; Baillie TA
    Curr Opin Drug Discov Devel; 2005 Jan; 8(1):44-50. PubMed ID: 15679171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Toxicity caused by so-called reactive metabolites of drugs].
    Pessayre D; Mazel P; Benhamou JP
    Nouv Presse Med; 1976 May; 5(18):1201-4. PubMed ID: 775438
    [No Abstract]   [Full Text] [Related]  

  • 20. [Clinical and toxicological significance of toxicity mechanisms].
    Gillmann H
    Arzneimittelforschung; 1977; 27(96):1819-20. PubMed ID: 579146
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.